Amylin Pharmaceuticals Shareholder?

October 10, 2013

Important Information is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects
Amylin Pharmaceuticals Shareholders
Allegations have surfaced that Amylin Pharmaceuticals failed to notify shareholders that it rejected a buyout offer from Bristol-Myers Squibb for $22 per share yet the insiders then awarded themselves new low-priced options.
Amylin Pharmaceuticals
Additional Details
In a shareholder derivative action, a shareholder theoretically files a claim on behalf of the corporation to protect its investors and to holder officers and directors accountable for improper management of the company.